Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Bevacizumab Plus Irinotecan (Camptosar) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas

Trial Profile

Phase II Study of Bevacizumab Plus Irinotecan (Camptosar) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Jun 2017 Results of an integrated analysis assessing the effects of bevacizumab on growth/development in pediatric/adolescent patients (n=403), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 29 Oct 2010 Planned End Date changed from 1 Sep 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top